Axsome Therapeutics (AXSM) stock gains as company settles patent dispute with Hikma (HKMPF) over sleep therapy Sunosi. Read ...

Looking ahead, revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 5.3% growth forecast ...

Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.

Hikma Pharmaceuticals PLC HIK shares dropped 6.18% to £21.54 Wednesday, on what proved to be an all-around positive trading ...

The Group reported revenue growth of 9% (9% in constant currency) to $3.127 billion compared to $2.875 billion in 2023) ...

Hikma's generics business, grew 9 per cent to $1.026 billion, surpassing the $1 billion revenue mark for the first time.

The pharmaceutical company said the bulk of its growth came from its North American arm as well as recent product launches ...

Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Hikma Pharmaceuticals (HKMPF), resolving patent ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on Hikma Pharmaceuticals (HIK – Research Report), with a ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Shares in Hikma Pharmaceuticals came under pressure in early trading on Wednesday, despite a jump in annual revenues, after ...